Rapid mAb Discovery Specialists

Abveris is a contract lab discovering monoclonal antibodies for reagent and therapeutic purposes. Using proprietary engineered in vivo systems, Abveris delivers hybridomas producing murine mABs to targets that cannot be found in natural in vivo systems.

Rapid Delivery Timelines

Delivery of custom-screened monoclonal hybridoma cell lines producing IgG monoclonal antibodies in tight timelines.

Science as a Service

The service component is important to us.

We provide a better antibody discovery service for the increasingly competitive biologics market.

An optimized in vivo platform

mAbs targeting non-immunogenic epitopes


The limiting factor in most in vivo antibody discovery platforms is the diversity of the immune response of the host animal. Abveris uses a proprietary rodent that has been engineered to express a more diverse antibody repertoire than regular animals. This enables the discovery of antibodies with specificities that cannot be found in other in vivo systems.

Natual Immune Reaction
DiversimAb Immune Reaction


Adding samples inside a biosafety cabinet

Anti-idiotypic mAbs

Our specialty! We screen for ideal PK/ADA reagents targeting IgG’s and funky molecules alike. Rapid delivery available.

Learn More
Scientist using pipette in a laboratory, horizontal

Therapeutic Antibody Discovery

Rapid discovery of diverse panels of mAbs custom screened to your specifications.

Learn More
Human papillomavirus HPV marked by antibodies

Cell surface targeting mAbs

DNA immunization, flow cytometry screening and other options are available.

Learn More

Reagent discovery

Panels of custom-screened mAbs delivered to your specifications. Difficult targets are welcome.

Learn More


“Abveris provided excellent services for antibody discovery. The clear communication, project flexibility and final data package made Devin a pleasure to work with.”

~ Colby Souders, Ph.D Kanyos Bio

“The team at Abveris was a pleasure to work with! They delivered a panel of antibodies that showed some mouse cross reactivity for a difficult target. They were able to stick to the aggressive timeline without compromising data quality.”

~ Scientist in the Boston area

“We counted on Abveris to generate antibodies against a difficult target and we received numerous antibodies that resulted in several functional leads to progress a high priority program. Have seen similar results in subsequent projects. Abveris is an essential element to our research efforts.”

~ Ramesh Bhatt,
Ph.D. – Co-Founder, Head of Research, COO at Torch Therapeutics


Devin Turner – Chief Scientific Officer, Founder

Devin has nearly 20 years of experience in the immunological sciences with specialties in cellular immunology, molecular immunology, and in vivo research models.

Since moving out of academia Devin has designed and managed antibody discovery campaigns against over 500 targets.

He is a passionate immunologist and father.

Dr. Turner earned his B.S. in Molecular, Cellular, and Developmental Biology from UCLA and Ph.D. in Immunology from the Division of Medical Sciences at Harvard University.

Garren Hilow – CEO, Co-Founder

Garren is an antibody enthusiast who has been working on the business side of biotherapeutics development since graduating business school.  Garren has managed antibody discovery platforms based on hybridomas, phage display, B-cell sequencing and now hybridomas again.

Garren earned his B.S. in Economics and Finance from Bentley University and is proud to be a new father.  He lives with his wife and son in Somerville, MA.

In off time Garren enjoys: fishing, hiking, Ultimate frisbee, mountain biking and camping.

Both Devin and Garren take customer’s satisfaction seriously and have always gone the extra mile to help our partners meet their goals.  Their passion is deep set in the Abveris culture.